How does Cannafarm Ltd. use blockchain and cloud technologies in its production?
Resumen
The post How does Cannafarm Ltd. use blockchain and cloud technologies in its production? appeared first on Coinpedia Fintech News Since 2018, a licensed British company, Cannafarm, has actively engaged in the production and supply of medical cannabis raw materials. Cannafarm’s products consist of distillates utilized within the pharmaceutical industry for the production of pain-relieving and antiepileptic drugs. Each ton of the organic distillate sold generates approximately $1,500,000 in revenue for the company. Cannafarm’s stability, market reputation, and profit are the results of the company’s investment in its own development. This ranges from automated farms in nine countries worldwide and a proprietary cultivation methodology allowing harvest every 35 days to progressive decentralized technologies integrated into production. Blockchain is not only decentralize finance. Blockchain was initially and most actively used in the financial environment as a tool to ensure transparency, security, and decentralization of payment systems. As a method of organizing and managing data, it has many advantages: Accessibility and openness of transaction information while maintaining the anonymity of network participants; Built-in mechanisms to counter unauthorized access, making it impossible to alter the data already entered into the blockchain; Automation of processes and reliability of transactions are ensures by smart contracts if they are use in the network. These advantages have demonstrated the potential of blockchain in various industries: medicine, insurance, pension funds, logistics, and manufacturing. So far, only a few companies, such as IBM, have integrated this technology into their business processes. The lack of enthusiasm in the market is primarily due to the complexity of integration: only large businesses with stable profits can afford a staff of specialists and the development of a complex decentralized ecosystem. Years of experience and growing demand for medical cannabis from pharmaceutical companies have allowed Cannafarm to modernize its productions and achieve certain successes. Currently, the company uses blockchain in the process of growing raw materials. Blockchain and Medical cannabis Legalization and usage of medical cannabis require constant control and transparency that will prevent the sale of raw materials on the black market, fraud, and violations of the law. Blockchain is the innovative, ideal solution that addresses this sector’s potential problems. In the case of Cannafarm, the blockchain ecosystem is use for the certification of batches of medical cannabis raw materials. As mentioned above, a new harvest is taken every 35 days and processed into a distillate supplied to the global market. Each batch receives a certificate of authenticity with data about the manufacturer and production dates. The decentralized architecture of the blockchain becomes the final touch: After each batch launch, its certificate is entered into the ecosystem using Ethereum smart contracts, creating a transaction. The transaction is stored in the blockchain and contains data about the certificate, its number, and the date of addition. Since blockchain is an open and immutable ledger, certificate data cannot be falsified or deleted. Still, they can be verified, thereby establishing its authenticity and the legality of the batch. Blockchain and Investments The versatility of blockchain technology has allowed Cannafarm to use it not only for batch control. The company’s investment proposal incorporates decentralized distributed ledger technology and cryptocurrencies, enabling every investor to actively participate in advancing the medical cannabis sector and realizing profits in this rapidly growing industry. Cannafarm offers four investment plans with up to 3% daily returns. The company uses the attracted financing to expand the production of new batches of raw materials. And it guarantees investor profits through the sale of products on the international market. Blockchain and smart contracts make the investment process transparent and secure. Only cryptocurrencies, including Ethereum and Bitcoin, are use for deposits. Which can withdrawn from the deposit at any time if the investor changes their mind for some reason. Such investments are convenient for the investor, anonymous, and guaranteed to yield returns, as they are manage by automated smart contracts. Cannafarm Ltd. is one of the first companies in the market to successfully implement the innovative capabilities of blockchain technology in various niches of its activities.
The Saudi National Bank (SNB), and Mastercard, the official sponsor of the UEFA Champions League, have partnered to launch the UEFA Champions League card …
Saudi National Bank and Mastercard launch Champions League cards
Banca
Resumen
The Saudi National Bank (SNB), and Mastercard, the official sponsor of the UEFA Champions League, have partnered to launch the UEFA Champions League card portfolio, the first of its kind in the Kingdom, offering cashback credit card and prepaid card without annual fees.
The post Ripple Vs SEC: John Deaton Predicts SEC Will Avoid Trial in Upcoming Case; Here’s Why appeared first on Coinpedia Fintech News Since the curtain …
Ripple Vs SEC: John Deaton Predicts SEC Will Avoid Trial in Upcoming Case; Here’s Why
Remesas · Criptodivisas
Resumen
The post Ripple Vs SEC: John Deaton Predicts SEC Will Avoid Trial in Upcoming Case; Here’s Why appeared first on Coinpedia Fintech News Since the curtain is open, SEC has few moves in Ripple vs. SEC. Our previous analysis explored the potential for the SEC to regroup after losing the interlocutory card. Is there someone who says the SEC will not take a trial path? Here’s why. Pro-Ripple legal expert John Deaton, known for his spot-on predictions, decodes a surprising twist in the XRP lawsuit. Despite a trial date set for April 2024 after the District Judge shot down the SEC’s bid for an early appeal, Deaton boldly predicts a trial might not even happen. Why? He has slender odds of SEC success, backed by weak evidence and hefty legal costs. The plot thickens, and the courtroom drama promises more surprises ahead. The SEC is in Pool of Questions? It is pretty evident so far that neither the SEC nor Gary Gensler has given any direct answer on various loopholes shown by the opponent. In a compelling discussion during a recent interview, Deaton questioned the real motives behind the SEC’s case, stating that “they died the moment they filed the case.” He hints that the SEC intends to force the securities laws but perhaps for other undisclosed reasons. This raises further questions about the SEC’s credibility and objectives in this landmark case. The SEC is likely to consider settlement talks with Ripple to end the legal battle, though it might be a tough call for regulators. Ripple’s case sets a precedent but doesn’t ensure similar outcomes for others. Deaton’s Stance on the Technicalities Deaton sees the recent decision as a significant setback for the SEC, making a trial unlikely. He questions how the SEC can prove its case when it’s against the law. XRP is considered innocent until proven otherwise. Deaton suggests the SEC might consider a settlement or drop the charges altogether to avoid the complexities of a trial. He also advises the SEC to hire a good lawyer if they aim to win. “Do they want all that Hinman stuff and the drama of a trial?” questioned Deaton, highlighting the complexities involved. Additionally, Deaton notes that the SEC is involved in other major legal battles with companies like Coinbase and Binance, diverting resources and adding complexity to their efforts. Deaton expresses confidence in Coinbase’s chances of winning but has reservations about Binance’s future trial outcome. XRP Ruling cannot be Tagged in All Cases However, legal expert John Deaton points out that this ruling’s scope is limited to XRP, not offering broader protection for other tokens. This leaves many projects in a regulatory gray area, potentially discouraging innovation in the U.S. While a step forward, the crypto industry still seeks comprehensive regulatory clarity for sustained growth and leadership in blockchain technology.
Generative artificial intelligence (AI) faces many growing pains as it seeks its footing. In a recent survey, management consulting firm Bain & Compan…
Generative AI’s Technology Is Not Yet Fully Optimized for Healthcare
Criptodivisas
Resumen
Generative artificial intelligence (AI) faces many growing pains as it seeks its footing. In a recent survey, management consulting firm Bain & Company reveals that the main barriers to generative AI in healthcare are a lack of resources, expertise and regulation, with data access and quality and organizational resistance close behind. The recurring theme across industry studies is that generative AI in healthcare is nascent and needs time to prove its efficacy and to earn public trust. Robust benchmarks will increase confidence. The lesson for technology companies, pharmaceutical firms and healthcare providers considering generative AI in their strategies is that the technology is not yet fully optimized for healthcare. For generative AI to bear fruit, it needs investors, technology, resources, expertise, LLMs trained with healthcare-specific data, and robust guidelines. Ultimately, society needs to be ready for and comfortable with the involvement of generative AI in managing patient health and treatment. The task ahead entails expanding resources and expertise, training models on healthcare-specific data and establishing robust benchmarks. In time, through multiple iterations, generative AI will sharpen its analysis. Developers will fine-tune the benchmarks and criteria used in their models, aligning them with emerging regulatory guidelines. The result will be improved accuracy in diagnoses and recommended treatments. Ethical guidelines and human readiness will shape generative AI use and governance. Regulators are urged to move fast, but doing so too quickly could bring unintended consequences. The same caution applies to technology companies that are eager to earn a profit from their innovations. AI tools that gain FDA approval are setting a precedent for what will become commonplace in the future. The potential downside may be that ethical dilemmas will prompt companies and regulators to reconsider their positions. According to a recent study, Americans have mixed feelings about the use of generative AI in their healthcare. While they are enthusiastic about the potential benefits, most Americans are hesitant to replace their medical professionals with this technology. These sentiments may shift over time as technology matures and regulatory guidelines become more robust.The post Generative AI’s Technology Is Not Yet Fully Optimized for Healthcare first appeared on PYMNTS.com.
The post Sam Bankman-Fried’s Trial Day 3: Shocking Information Revealed! appeared first on Coinpedia Fintech News On October 5th, the prosecution cross-ex…
Sam Bankman-Fried’s Trial Day 3: Shocking Information Revealed!
Prestamos · Criptodivisas
Resumen
The post Sam Bankman-Fried’s Trial Day 3: Shocking Information Revealed! appeared first on Coinpedia Fintech News On October 5th, the prosecution cross-examined Adam Yedidia about a significant $8 billion financial matter connecting Alameda and FTX. Yedidia, a close friend of Sam Bankman-Fried and a former FTX developer, also resided at Bankman-Fried’s lavish $35 million Bahamas property. This is a story of finances, yes, but also one of trust, betrayal, and much more. Read on. The $8 Billion Puzzle Yedidia revealed that in early 2021, FTX had transferred user funds to an Alameda account called “North Dimension” because they faced difficulties securing a regular bank account. This transfer created an $8 billion obligation for Alameda towards FTX by June 2022. Surprisingly, Yedidia knew about this transfer in 2021 but didn’t think much of it. However, his perspective changed in 2022 when he learned of the enormous debt. He discussed his concerns with Bankman-Fried during a game of tennis. SBF's Lisner: So there not being an FTX board did not stop you from investing?Judge Kaplan: Obviously… Come to the sidebar.[The lawyers head up. This we cannot hear. Then, witness is done.[Next witness: Gary Wang.AUSA: What was your job at FTX?Wang: CTO— Inner City Press (@innercitypress) October 5, 2023 Yedidia claims that Bankman-Fried stated that the companies should pay off their debt within six months to three years. Yedidia expressed his concern to Bankman-Fried, emphasizing the urgency of paying off the debt. Bankman-Fried assured Yedidia that they would prioritize resolving the obligation and explore various strategies to expedite repayment. Under questioning, Yedidia expressed his trust in Sam Bankman-Fried, Caroline, and others at Alameda to handle the situation responsibly. However, his trust was shattered when he discovered in November 2022 that Alameda not only retained the funds but also used them to pay off its own debts. Also Read: FTX Co-Founder Testifies That Sam Bankman-Fried Committed Wire Fraud! Testimonies from Key Figures The October 5th trial also featured testimony from Gary Wang, co-founder of FTX and Alameda Research, and Matthew Huang, co-founder of Paradigm. Paradigm had invested $278 million in FTX between 2021 and 2022 through two fundraising rounds. FTX Co-Founder Gary Wang Testifies in Bankman-Fried's TrialIn a significant turn of events during the ongoing trial of FTX founder Sam Bankman-Fried, Gary Wang, FTX's co-founder and Bankman-Fried's former college roommate at MIT, took the stand. Wang's testimony shed light… pic.twitter.com/MyCyjWiglu— Gokhshtein (@gokhshtein) October 6, 2023 Admissions and Perks During his brief testimony, Gary Wang admitted to engaging in wire fraud, securities fraud, and commodities fraud, alongside Bankman-Fried, Caroline Ellison, and others. Wang also disclosed Alameda’s unique advantages within FTX, such as a massive $65 billion credit line and unlimited fund withdrawals, unlike other market makers. FTX insider Gary Wang said Sam Bankman-Fried allowed Alameda to withdraw unlimited funds— Whale (@WhaleChart) October 5, 2023 There were reports of a potential $200 million to $300 million loan from Alameda for cryptocurrency ventures, although these loans were not recorded in Wang’s account. Wang’s testimony was scheduled to continue on October 6th. Defense Responds In response to the prosecution’s claims of fund mixing, Bankman-Fried’s defense sought to provide the jury with a broader understanding of FTX and Alameda’s connection. They highlighted FTX’s rapid expansion and the long hours worked by Bankman-Fried and senior team members during the bullish 2021 market. The defense also mentioned the Securities and Exchange Commission’s offer of immunity to Yedidia, protecting him from accountability for his involvement at FTX, in exchange for his cooperation. Also Read: FTX Margin System Controversy: Was CEO Bankman-Fried Defrauding Investors? Furthermore, the defense stressed that FTX’s difficulty in obtaining a bank account and its reliance on Alameda’s ‘North Dimension’ for fund deposits were widely recognized in the industry. The cross-examination of Yedidia was set to resume in the afternoon, in the federal courtroom in lower Manhattan.